Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND
Status:
Suspended
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
In patients after myocardial infarction (MI) (heart attacks) and treated with percutaneous
coronary intervention (PCI), the current standard is dual antiplatelet therapy (DAPT), with
aspirin and a P2Y12 receptor inhibitor, for 1 year of treatment. At 1 year, there are several
options including: i) Ongoing DAPT (with aspirin and ticagrelor), ii) Selective treatment use
of a P2Y12 inhibitor based on risk profiles.
This study is a pilot vanguard study to evaluate several strategies for choosing
anti-platelet regimen among patients post MI and PCI at 1 year.